Home Companies Catalysts Deep Dives
Prograf tacrolimus APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaImmunology
Launch1994-04-08
US LOE2008-04-01
Peak Sales Est$2000M
Formulations[{"id":"prograf-capsule","route":"PO","setting":"PATIENT_SELF","frequency":"Twice daily","is_primary
Companies
ALPMY (ORIGINATOR)100%
Mechanism: Calcineurin inhibitor
Expert: Calcineurin inhibitor blocking T-cell activation for transplant immunosuppression.
Everyday: Suppresses immune system to prevent organ rejection.
Targets: ["CALCINEURIN"]
Revenue History
PeriodRevenue ($M)
FY2023$1,100M
FY2024$950M
Programs (1)
IndicationStageKey StudyRegional Status
Solid organ transplantAPPROVEDMultiple pivotal trials[{"stage":"APPROVED","region":"US","approval_date":"1994-04-08"}]
Notes
Transplant immunosuppression. Legacy product, generic competition. LOE Note: Generic competition exists but Prograf maintains market share due to NTI status and physician preference.
Data from Supabase · Updated 2026-03-24